

Breast Cancer Breast Cancer Er-Positive Breast Cancer HER-2 Negative

## A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

### Trial Status

Active, not recruiting

### Trial Runs In

5 Countries

### Trial Identifier

NCT03332797 2017-002083-41  
GO39932

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### *Trial Summary:*

This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with palbociclib and/or luteinizing hormone-releasing hormone (LHRH) agonist in participants with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.

### Genentech, Inc.

Sponsor

### Phase 1

Phase

NCT03332797 2017-002083-41 GO39932

Trial Identifiers

### *Eligibility Criteria:*

#### Gender

Female

#### Age

>= 18 Years

#### Healthy Volunteers

No